Monteris Medical's NeuroBlate System Shows Promise in Minimally Invasive Treatment for Epilepsy

Strategic Insights -

Researchers at Monteris Medical have announced a groundbreaking study published in JAMA Neurology, highlighting the effectiveness of their NeuroBlate System in treating drug-resistant mesial temporal lobe epilepsy (MTLE). The study, which drew from Monteris' LAANTERN research initiative, involved 145 patients across 15 U.S. institutions and demonstrated long-term seizure freedom outcomes comparable to traditional surgery. The NeuroBlate procedure, a minimally invasive laser interstitial thermal therapy (LITT), offers a safer and more durable alternative to traditional brain surgery, with patients experiencing short hospitalizations, low readmission rates, and positive recovery outcomes.

Key Takeaways:

  • The study, published in JAMA Neurology, is the largest prospective analysis to date of LITT for drug-resistant epilepsy, involving 145 patients across 15 U.S. institutions.
  • The NeuroBlate System demonstrated long-term seizure freedom outcomes comparable to anterior temporal lobectomy (ATL), with 58.4% and 57.2% of patients achieving Engel 1 and International League Against Epilepsy (ILAE) 1/2 seizure freedom classifications at one and two years, respectively.
  • The study showed that patients experienced short hospitalizations, low readmission rates, and positive recovery outcomes, with nearly all discharged to their homes post-procedure.
  • The NeuroBlate procedure, a minimally invasive laser interstitial thermal therapy (LITT), offers a safer and more durable alternative to traditional brain surgery, with patients experiencing less pain, shorter hospital stays, and fewer complications.
  • Quality of life (QoL) improvements were observed at nearly every measured time point, highlighting the impact of minimally invasive NeuroBlate on patient well-being.
  • Over one-third (34.9%) of patients either stopped or reduced their use of anti-seizure medications following the procedure, emphasizing its long-term benefits.

Statistics:

  • 58.4% of patients achieved Engel 1 seizure freedom classification at one year.
  • 57.2% of patients achieved International League Against Epilepsy (ILAE) 1/2 seizure freedom classification at two years.
  • 34.9% of patients stopped or reduced their use of anti-seizure medications following the procedure.
  • Nearly all patients were discharged to their homes post-procedure.
  • Short hospitalizations and low readmission rates were observed in patients undergoing the NeuroBlate procedure.

Sources:

  • Monteris Medical news release
  • JAMA Neurology study
  • LAANTERN research initiative
  • Study lead author, Dr. Patrick Landazuri, Professor of Neurology at the University of Kansas Medical Center in Kansas City, Kan.